Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations

INTRODUCTION: Savolitinib has been found to have encouraging antitumor activity and a favorable safety profile in Chinese patients with pulmonary sarcomatoid carcinoma and other NSCLCs with MET exon 14 skipping alterations (MET ex14 positive) at the primary analysis of a phase 2 study. Here, we pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Shun, Fang, Jian, Li, Xingya, Cao, Lejie, Zhou, Jianying, Guo, Qisen, Liang, Zongan, Cheng, Ying, Jiang, Liyan, Yang, Nong, Han, Zhigang, Shi, Jianhua, Chen, Yuan, Xu, Hua, Zhang, Helong, Chen, Gongyan, Ma, Rui, Sun, Sanyuan, Fan, Yun, Fan, Songhua, Yu, Jie, Lu, Puhan, Luo, Xian, Su, Weiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547292/
https://www.ncbi.nlm.nih.gov/pubmed/36217329
http://dx.doi.org/10.1016/j.jtocrr.2022.100407

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547292/
https://www.ncbi.nlm.nih.gov/pubmed/36217329
http://dx.doi.org/10.1016/j.jtocrr.2022.100407

Ejemplares similares